ストックスクリーナーアプリを入手
0.43
0.00%
0.00
アフターアワーズ：
.41
-0.02
-4.65%
前日終値:
$0.43
開ける：
$0.41
24時間の取引高:
1.93M
Relative Volume:
0.26
時価総額：
$22.28M
収益：
-
当期純損益:
$-563.30K
株価収益率:
-2.1543
EPS:
-0.1996
ネットキャッシュフロー:
$-22.23M
1週間 パフォーマンス:
-20.36%
1か月 パフォーマンス:
-35.82%
6か月 パフォーマンス:
-44.73%
1年 パフォーマンス:
-68.59%
1日の値動き範囲:
$0.3977
$0.45
1週間の範囲:
$0.3977
$0.5466
52週間の値動き範囲:
$0.38
$1.59
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
PMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.43 | 22.28M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc (PMN) 最新ニュース
Applying Wyckoff theory to ProMIS Neurosciences Inc. stockWeekly Market Summary & Free Expert Verified Stock Movement Alerts - Newser
Using economic indicators to assess ProMIS Neurosciences Inc. potentialFed Meeting & Proven Capital Preservation Methods - Newser
Technical analysis overview for ProMIS Neurosciences Inc. stockWeekly Profit Recap & Verified High Yield Trade Plans - Newser
What’s the recovery path for long term holders of ProMIS Neurosciences Inc. - Newser
Is ProMIS Neurosciences Inc. stock entering bullish territoryQuarterly Portfolio Report & Verified High Yield Trade Plans - Newser
Market reaction to ProMIS Neurosciences Inc.’s recent newsMarket Activity Recap & Community Verified Watchlist Alerts - Newser
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss - MSN
Promis Neurosciences (NASDAQ:PMN) and Beam Therapeutics (NASDAQ:BEAM) Critical Survey - Defense World
ProMIS Neurosciences files to sell 28.23M common shares for holders - MSN
ProMIS Neurosciences Plunges 11.63% on SEC Filing - AInvest
Smart tools for monitoring ProMIS Neurosciences Inc.’s price actionSwing Trade & Real-Time Volume Triggers - Newser
ProMIS Neurosciences Inc. stock trend outlook and recovery pathTreasury Yields & Fast Moving Stock Trade Plans - Newser
ProMIS Neurosciences' Secondary Equity Offering: Strategic Motivations and Market Implications - AInvest
ProMIS Neurosciences Inc. stock trend forecastPortfolio Value Report & Low Drawdown Investment Strategies - Newser
What MACD signals say about ProMIS Neurosciences Inc.Quarterly Profit Report & Growth Focused Entry Reports - Newser
ProMIS Neurosciences (PMN) Files Prospectus for Sale of 28.23M S - GuruFocus
ProMIS Neurosciences files prospectus of 28.2 mln common shares offering relates to resale by selling securityholders - MarketScreener
ProMIS Neurosciences' Share Offering and Its Implications for Shareholder Value and Market Perception - AInvest
Does ProMIS Neurosciences Inc. have a sustainable dividend2025 Year in Review & AI Enhanced Market Trend Forecasts - خودرو بانک
Has ProMIS Neurosciences Inc. formed a bullish divergenceWeekly Profit Recap & Pattern Based Trade Signal System - Newser
ProMIS Neurosciences shares fall 7.88% premarket despite positive trial updates and approvals. - AInvest
Will ProMIS Neurosciences Inc. see short term momentumEarnings Beat & Daily Technical Stock Forecast Reports - Newser
Using data tools to time your ProMIS Neurosciences Inc. exitMarket Growth Report & Technical Entry and Exit Alerts - Newser
Sector ETF performance correlation with ProMIS Neurosciences Inc.Risk Management & Consistent Profit Alerts - Newser
Why ProMIS Neurosciences Inc. is moving todayEarnings Overview Summary & Weekly Top Stock Performers List - Newser
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310 - Ariva
Live market analysis of ProMIS Neurosciences Inc.July 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
ProMIS Neurosciences' PMN310: A Safer, Differentiated Alzheimer’s Therapy with Strong Clinical and Regulatory Momentum - AInvest
ProMIS Neurosciences Gets Approval to Advance Alzheimer's Disease Treatment to Final Dose Escalation - MarketScreener
ProMIS Neurosciences advances Alzheimer's trial to final dose escalation cohort. - AInvest
ProMIS Neurosciences Receives DSMB Approval to Advance to - GlobeNewswire
ProMIS Neurosciences Receives DSMB Approval for PMN310 Alzheimer's Trial to Advance to Final Dose Cohort. - AInvest
Zero ARIA Cases: ProMIS's Novel Alzheimer's Drug PMN310 Advances to Final Trial Phase with Clean Safety Data - Stock Titan
Ranking ProMIS Neurosciences Inc. among high performing stocks via toolsWeekly Risk Summary & Weekly Momentum Picks - Newser
What indicators show strength in ProMIS Neurosciences Inc.Weekly Stock Report & Short-Term High Return Ideas - Newser
Relative strength of ProMIS Neurosciences Inc. in sector analysisWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
ProMIS Neurosciences Inc. stock outlook for YEARJuly 2025 Update & Real-Time Chart Pattern Alerts - Newser
Visualizing ProMIS Neurosciences Inc. stock with heatmaps2025 Technical Overview & Smart Investment Allocation Tips - Newser
Volatility clustering patterns for ProMIS Neurosciences Inc.2025 Market Sentiment & Daily Market Momentum Tracking - Newser
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):